Wait your data is sending.

Welcome to the RIGHT THERAPY CONTEST 2019

As the leader in adsorptive extracorporeal blood depuration therapies Bellco, now part of Medtronic, is pleased to provide an opportunity to exchange relevant clinical experience to assess the impact of adsorptive dialysis therapies on your patient’s quality of life.

The goal of this contest is to facilitate healthcare professionals' collaboration and to share clinical best practice and application of adsorptive therapies.

Medtronic has a 40-year legacy of innovation that addresses the uniqueness of each patient and how personalization of treatment, the Right Therapy, can potentially lead to improved outcomes.

We invite you to share your case through the Right Therapy Contest website for review and consideration for sharing with your interested peers across the European geography.

Thank you in advance for your collaboration

Medtronic Renal Care Solutions Team

THE CONTEST

REGISTER

UPLOAD YOUR CASE

AWARDS

REGISTER TO PARTECIPATE IN THE CONTEST

Your information will be protected in accordance with our privacy statement.

UPLOAD YOUR CASE

(You have characters left for this form. Fields with asterisk * are mandatory)
UPLOAD YOUR FIGURES/TABLES
(maximum 2 files, up to 5MB each)
THE CONTEST

The aim of the contest is to collect Case Reports and/or clinical experiences on hemodialysis patients treated with Bellco adsorptive extracorporeal therapies as part of standard clinical practice. The contest is open to physicians based in Europe. An independent jury will evaluate the submissions and announce the best three Case Reports.

CASE REPORT FORMAT

All Case Reports need to be composed of the following:

  • Title: clearly stating the object of the Case Report;
  • Authors & affiliations;
  • Background: brief introduction of the topic and the patient characteristics (comorbidities, pathologies, etc.);
  • Methods: a brief description on how the data has been collected;
  • Results: briefly, the main result of the Case Report;
  • Conclusions;
  • References.

All data collected should refer to patients that have already been treated with Bellco therapies. Data should be retrospective, including both published and non-published Case Reports.
Case Reports cannot contain confidential or sensitive patient information, that could directly or indirectly identify a patient (e.g. name, age, date of treatment etc.). We reserve the right to censor the data provided if it contains confidential or sensitive patient data.
Data from ongoing clinical trials or collected specifically for the purpose of this contest will be excluded.

SELECTION CRITERIA

The scientific committee will evaluate every single submission based on the following criteria:

  1. Originality and uniqueness of cases;
  2. Level of detail;
  3. Impact on the patient's quality of life.
DEADLINE

The authors can register and submit the Case Report on website from November 19, 2018.
The closing date for submissions is May 3 May 5, 2019, 23.59 CET. Case Reports received after this date cannot be considered.

PUBLICATIONS

The authors of the three best abstracts will be invited to present their case at a Medtronic event.
At the end of the contest, all Case Reports will be collected and published in a special edition booklet, to be distributed by Medtronic, after approval from the authors.

SCIENTIFIC COMMITTEE

The jury, formed by two European clinicians, has been selected by the Bellco Scientific Affairs Team based on their scientific curricula, expertise, and their experience with Bellco filtration adsorption therapies. The jury has no conflict of interest with Medtronic.
Further jury selection criteria includes the following:

  • at least two publications on Bellco adsorptive therapies and/or extracorporeal blood purification therapies;
  • at least 10 publications on peer-reviewed international journal (definition of Key Opinion Leader);
  • deep knowledge on uremic toxin and effect on patients in dialysis.

AWARDS

A Master class meeting was held in Bologna on July 4th with the winners that had the opportunity to present their cases. Differently from the contest rules, the Jury final evaluation assigned 5 best cases divided into the following categories: Patients with Cardiovascular Risk, Patients with Inflammation and Malnutrition, Miscellaneous.

PUBLICATION

Category 1: Patients with Cardiovascular Risk

  • Author: Marco RIGHETTI (Italy).
    Title: HFR aequilibrium® improves intradialytic hypotension in hemodialysis patients
  • Author: Lucile MERCADAL (France).
    Title: Isonatric dialysis biofeedback in hemodiafiltration with online regeneration of ultrafiltrate (HFR) in hypertensive hemodialysis patients: a randomized controlled study
booklet category 1

Category 2: Patients with Inflammation and Malnutrition

  • Author: Luca DI LULLO (Italy).
    Title: Reduction of pro – inflammatory biomarkers and erythropoiesis stimulating agents (ESAS) consumption in hemodiafiltration reinfusion (HFR) – treated patient: a case report
  • Author: Vincenzo LOSAPPIO (Italy).
    Title: Hemodiafiltration with on-line endogenous reinfusion (HFR) and cytokines (CK) removal: a center experience
booklet category 2

Category 3: Miscellaneous

  • Author: Tania MONZON (Spain).
    Title: Use HFR-supra for porphyria cutanea tarda treatment in hemodialysis patient
booklet category 3

RIGHT THERAPY CONTEST 2019 download all cases

booklet all cases

 

THE RIGHT THERAPY FOCUS

Patients on dialysis can be challenging to treat due to many factors including advanced age and multiple comorbidities. A bibliography of clinical successes, published in relevant scientific journals or presented at international congresses, is reported on the following table to illustrate where clinical needs and dedicated therapies meet. Sharing these clinical best practices enables us to expand knowledge and understanding of this complex patient issue, and work together to address future challenges.

In the Right Therapy Table, you will find all references on Bellco Therapy solutions for patients in hemodialysis:

  • Adsorptive therapies HFR (hemodiafiltration with endogenous reinfusion) and SUPRA;
  • MID-dilution HDF on-line, that combines post-dilution and pre-dilution (NOT involved in this contest).


Click below to access the selection of articles related to adsorptive therapies in patients with the following conditions.

 
Medtronic
RTC 2019
© 2019 Medtronic
Terms of Use
Privacy Statement
For all other enquiries, please email support@righttherapycontest.com